GlaxoSmithKline: HIV Infections trials

The registry lists 265 HIV Infections studies with GlaxoSmithKline as lead sponsor. 15 are open to participants now and 99 have results posted.

Phase 1 84Phase 2 53Phase 3 68Phase 4 18No phase 47(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive SubjectsCompletedNCT00549198Phase 4Results posted
• Multicenter Pilot Study To Define The Marker As An Alternate For Tropism AssayTerminatedNCT00496782Phase 1Results posted
• Multicenter, Safety Study Of MaravirocCompletedNCT00478231Phase 3Results posted
• Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionCompletedNCT00440947Phase 3Results posted
• Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative VolunteersCompletedNCT00434512Phase 2Results posted
• Expanded Access Program for Maraviroc At Multiple CentersCompletedNCT00426660Phase 3Results posted
• A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected SubjectsCompletedNCT00363142Phase 3Results posted
• Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIVCompletedNCT00244712Phase 4Results posted
• Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected SubjectsCompletedNCT00098748Phase 2/3Results posted
• Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedNCT00098722Phase 2/3Results posted
• Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedNCT00098306Phase 2/3Results posted
• 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV InfectionCompletedNCT00089583Phase 2Results posted
• Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric SubjectsCompletedNCT00071760Phase 2Results posted
• A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 YearsCompletedNCT00040664Phase 2Results posted
• A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy AdultsCompletedNCT07066722Phase 1
• A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVActive, not recruitingNCT07053384Phase 1
• A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVActive, not recruitingNCT06970223Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsActive, not recruitingNCT06786520Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Active, not recruitingNCT06741397Phase 2
• A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1Active, not recruitingNCT06694805Phase 3
• A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVTerminatedNCT06652958Phase 1
• VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)WithdrawnNCT06533280Phase 1
• A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy ParticipantsCompletedNCT06368986Phase 1
• A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female ParticipantsCompletedNCT06310616Phase 1
• A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy ParticipantsCompletedNCT06168318Phase 1
• Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Active, not recruitingNCT06134362Phase 3
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult ParticipantsCompletedNCT06033547Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy AdultsCompletedNCT06012136Phase 1
• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingNCT05996471Phase 2
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingNCT05979311Phase 3
• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyCompletedNCT05917509Phase 3
• A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) FormulationCompletedNCT05776108Phase 1
• A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) ActivityCompletedNCT05631704Phase 1
• Low-dose Fostemsavir Extended Release Relative Bioavailability StudyCompletedNCT04757974Phase 1
• Real-world Insights of People With Human Immunodeficiency Virus (HIV) InfectionCompletedNCT03400293
• Phase 4 Study of Dolutegravir (DTG) in Russian FederationCompletedNCT03314064Phase 4
• Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With MenCompletedNCT03310515
• Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)CompletedNCT02741557Phase 1
• A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)CompletedNCT02674581Phase 1
• Taste Properties of HIV InhibitorCompletedNCT02608918Phase 1
• Study on Effects of BMS-955176 on the Pharmacokinetics of Probe SubstratesCompletedNCT02578277Phase 1
• A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy VolunteersCompletedNCT02354950Phase 1
• Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal ImpairmentCompletedNCT02354937Phase 1
• Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in GermanyCompletedNCT02342769
• Study on PharmacokineticsCompletedNCT02234882Phase 1
• Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.CompletedNCT02206711Phase 1
• Dolutegravir Expanded Access StudyCompletedNCT01536873Not applicable
• GSK1349572 Hepatic Impairment StudyCompletedNCT01231529Phase 1
• A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.TerminatedNCT01195974Phase 1
• Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy VolunteersCompletedNCT01068925Phase 1
• Effect Of Maraviroc On The Pharmacokinetics Of DigoxinCompletedNCT01056874Phase 1
• HIV Treatment and CVD EventsCompletedNCT01054638
• A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761CompletedNCT01031472Phase 1
• GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose StudyCompletedNCT00942136Phase 1
• Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years OldCompletedNCT00814762Phase 1
• Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.CompletedNCT00812318Phase 1
• A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744CompletedNCT00659191Phase 1
• Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency VirusCompletedNCT00643643Phase 2
• Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency VirusCompletedNCT00634959Phase 2
• Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected PatientsCompletedNCT00481390
• Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701CompletedNCT00453440
• Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected AdultsCompletedNCT00449436Phase 4
• A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701CompletedNCT00435838
• A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.CompletedNCT00386347Phase 1
• HLA-B*5701 And Hypersensitivity To AbacavirCompletedNCT00373945
• Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected AdultsCompletedNCT00343941Phase 2
• Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir HypersensitivityCompletedNCT00340080Phase 4
• Pharmacokinetic Study Of EPZICOM TabletCompletedNCT00337922Phase 4
• Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable VirusTerminatedNCT00321438
• Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected SubjectsCompletedNCT00320307Phase 1
• Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected SubjectsTerminatedNCT00297076Phase 3
• GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected AdultsCompletedNCT00257621Phase 2
• Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)CompletedNCT00242840Phase 3
• Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected SubjectsTerminatedNCT00197197Phase 3
• Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140TerminatedNCT00123890Phase 3
• Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral TherapyCompletedNCT00114699Phase 1
• GW873140 In Combination With Combivir In HIV Infected SubjectsTerminatedNCT00104429Phase 2
• GW873140 In Combination With Kaletra In HIV Infected SubjectsTerminatedNCT00102778Phase 2
• A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)CompletedNCT00094367Phase 3
• Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected AdultsCompletedNCT00090077Phase 1
• KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 WeeksCompletedNCT00085943Phase 3
• A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIVCompletedNCT00082394Phase 4
• A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior TherapyCompletedNCT00053638Phase 3
• A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected PatientsCompletedNCT00046332Phase 2
• A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsCompletedNCT00046176Phase 3
• New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected SubjectsCompletedNCT00044577Phase 3
• Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIRCompletedNCT00043888Phase 3
• Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic FailureCompletedNCT00038506Phase 4
• Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological FailureStatus unknownNCT00025727Phase 3
• Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsStatus unknownNCT00011895Phase 4
• Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral DrugsStatus unknownNCT00009061Phase 3
• Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral TherapyStatus unknownNCT00008554Phase 3
• A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive PatientsCompletedNCT00005764Phase 4
• A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected PatientsStatus unknownNCT00005663Phase 3
• A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected PatientsCompletedNCT00005106Phase 4
• Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentCompletedNCT00005018Phase 4
• Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received TreatmentStatus unknownNCT00005017Phase 4
• Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)Status unknownNCT00004981Phase 3
• Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV DrugsCompletedNCT00004852Phase 2
• A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected AdultsCompletedNCT00004585Phase 4